Gastrointestinal Cancer News

CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.

CHICAGO — An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation, study results showed.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

Individuals who ranked highest on a scale measuring social vulnerability by location had a poorer prognosis following colorectal resection, according to a presentation at Southern Surgical Association Annual Meeting.

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.

Researchers at Montefiore Einstein Comprehensive Cancer Center have developed an AI-based patient navigation tool that may increase completion of colonoscopies among individuals who canceled or did not show for an initial appointment.

An FDA advisory committee has voted strongly in favor of approval for Guardant Health’s blood test for colorectal cancer, intended for patients aged 45 years and older at average risk for disease.

Men vaccinated for HPV less frequently developed all related cancers, particularly head and neck cancers, according to findings scheduled for presentation at ASCO Annual Meeting.